IL-2/anti-IL-2 complexes, with specificity toward the intermediate- or high-affinity IL-2R, support improved antitumor immunity in comparison to IL-2 when used as a monotherapy (116–118) or as potentiators of tumor vaccines. The gene discussed is IL2RA; the disease is neoplasm.